Patient groups push back against Gilead's pricey HIV prevention treatment

Reuters

7 August 2019 - Gilead Sciences hopes to soon introduce a pricey new pill to prevent HIV in people at risk of contracting the infection, but the drugmaker faces opposition from an unusual source: patient advocates.

Such groups have traditionally lobbied for insurance coverage of newer HIV drugs regardless of expense. But at least three U.S. organisations now question whether Gilead’s Descovy would be the best option for most people at risk of exposure.

A generic version of the current prevention pill, Truvada, is due in the United States in September 2020, which should bring down costs and give many more people access to the therapy, they say.

Read Reuters article

Michael Wonder

Posted by:

Michael Wonder